

The PHASE Story

PHASESCIENTIFIC INDICAID™

- 2015 PHASE Scientific was founded, focusing on new technologies for infectious disease and oncology diagnostics
- 2020 Pivoted to COVID-19 product development and testing
- 2021 FDA EUA for INDICAID COVID-19 Rapid Antigen Test (POC)
- 2022 FDA EUA for INDICAID COVID-19 Rapid Antigen At-Home Test (OTC)
- 2024 Expanded INDICAID rapid test lines, including pregnancy (hCG), ovulation (LH), UTI and iFOB tests
- 2025 Brought to market the first ever HPV urine diagnostic test
Launched FebriDx®, a rapid, point-of-care fingerstick test that differentiates bacterial acute respiratory infections from non-bacterial etiology after 10 minutes
Expanded respiratory test portfolio with 510(k) cleared COVID-19/Flu A&B
- 2026 CLIA Waiver granted for FebriDx, expanding point-of-care access nationwide

A purpose-built diagnostic platform

Agile & responsive

We stay ahead of the curve by developing smart, fast solutions that reflect real-time trends and address emerging health needs.

Tailored diagnostic solutions

Our products are built with patients and providers in mind to improve access, adherence, and real-world outcomes.

Human-centered science

Every innovation is rooted in rigorous science with a focus on usability, empathy, and clarity.

PHASESCIENTIFIC

PHASESCIENTIFIC



PHASiFY®

PHASiFY is a proprietary technology used to pioneer new diagnostics for infectious diseases and cancer. It improves diagnostic sensitivity by concentrating target biomolecules from patient samples. By enriching sample quality, PHASiFY enhances test performance while reducing costs—enabling earlier and more accurate disease detection.

LEARN MORE

Partner with PHASE

Contact us to request samples or place an order.

- 🌐 phasescientificamericas.com
- 📞 657-233-5880
- ✉️ USSales@phasesci.com
- 📍 10527 Garden Grove Blvd
Garden Grove, California 92843



Diagnostics, redefined

Supporting patients and healthcare providers through the creation of innovative diagnostic tests and tools that enable people to better understand their own health



COMING SOON

HPV URINE TEST

A non-invasive detection of 14 HPV subtypes

Human papillomavirus (HPV) is the most common sexually transmitted and persistent infection, and is the leading cause of cervical cancer. Over 99% of cervical cancer cases are caused by HPV¹, with subtypes 16 and 18 alone responsible for about 70% of cases.

Our HPV Urine Test uses a simple, self-collected urine sample to deliver high-quality DNA-based detection of 14 high-risk HPV subtypes.



99%
of all cervical cancers
are caused by HPV¹

Broad portfolio. Rapid results.

We offer a growing portfolio of OTC and POC rapid tests for infectious diseases, reproductive health, and more—delivering fast, actionable results when it matters most.



Respiratory

- COVID-19
- COVID-19 / Flu A&B
- FebriDx (bacterial vs. non-bacterial acute respiratory infection)
- Rapid Strep A



Women's health

- HPV Urine
- Pregnancy
- Ovulation



General health

- UTI
- Fecal Occult Blood Test (IFOB)



Emerging Diagnostics

- Fentanyl Drug Detection
- Fentanyl Rapid Detection for harm reduction
- Xylazine Rapid Detection for harm reduction
- Multi-Drug Urine

Benefits and features

Non-invasive & private

Self-collection at home or in a healthcare setting

Accurate results

Proprietary PHASiFY™ technology ensures high performance, comparable to provider-collected cervical samples²

Comprehensive testing

Detects 14 HPV subtypes, including individual reporting of the two highest-risk (HPV 16 & 18)

Fast turnaround

Results ready in 3–5 business days

Supports prevention & care

HPV testing can help healthcare providers determine if additional care is warranted

¹Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608.

²Phase Scientific HPV Urine Test Performance Validation Study comparing the PHASE Lab HPV Urine Test to an FDA approved HPV test using physician collected cervical samples yielded 93% concordance.

